Epidemiology and management of gout in Taiwan: A nationwide population study

Arthritis Research and Therapy

Volumn 17, Issue 1, 2015, Pages

  Kuo, Chang Fu ^a,b   Grainge, Matthew J ^c   See, Lai Chu ^d,e   Yu, Kuang Hui ^b   Luo, Shue Fen ^b   Zhang, Weiya ^a   Doherty, Michael ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^e CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; BENZBROMARONE; PROBENECID; SULFINPYRAZONE; URATE; URICOSURIC AGENT; XANTHINE OXIDASE INHIBITOR; ANTIGOUT AGENT;

ADULT; AGED; ARTICLE; DRUG USE; FEMALE; GOUT; HUMAN; INCIDENCE; INDIGENOUS PEOPLE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; POPULATION STRUCTURE; PRESCRIPTION; PREVALENCE; SEX DIFFERENCE; TAIWAN; URBAN AREA; VERY ELDERLY; AGE DISTRIBUTION; MIDDLE AGED; SEX RATIO; YOUNG ADULT;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; FEMALE; GOUT; GOUT SUPPRESSANTS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PREVALENCE; SEX DISTRIBUTION; TAIWAN; YOUNG ADULT;

EID: 84924288237     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-015-0522-8     Document Type: Article

References (54)

1. Smith E, Hoy D, Cross M, Merriman TR, Vos T, Buchbinder R, et al. The global burden of gout: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. 2014;73:1470-6. doi:10.1136/annrheumdis-2013-204647.
2. Wortmann RL, Schumacher HR, Becker MA, Ryan LM, editors. Crystal-induced arthropathies: gout, pseudogout, and apatite-associated syndromes. New York: Taylor & Francis. 2006.
3. Doherty M, Jansen TL, Nuki G, Pascual E, Perez-Ruiz F, Punzi L, et al. Gout: why is this curable disease so seldom cured? Ann Rheum Dis. 2012;71:1765-70.
4. Kuo CF, Yu KH, See LC, Chou IJ, Tseng WY, Chang HC, et al. Elevated risk of mortality among gout patients: a comparison with the national population in Taiwan. Joint Bone Spine. 2011;78:577-80.
5. Kuo CF, See LC, Luo SF, Ko YS, Lin YS, Hwang JS, et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology (Oxford). 2010;49:141-6.
6. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116:894-900.
7. Roddy E, Zhang W, Doherty M. The changing epidemiology of gout. Nat Clin Pract Rheumatol. 2007;3:443-9.
8. Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 2014. doi:10.1136/annrheumdis-2013-204463.
9. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63:3136-41.
10. Chou CT, Pei L, Chang DM, Lee CF, Schumacher HR, Liang MH. Prevalence of rheumatic diseases in Taiwan: a population study of urban, suburban, rural differences. J Rheumatol. 1994;21:302-6.
11. Chang SJ, Ko YC, Wang TN, Chang FT, Cinkotai FF, Chen CJ. High prevalence of gout and related risk factors in Taiwan's Aborigines. J Rheumatol. 1997;24:1364-9.
12. Chou CT, Lai JS. The epidemiology of hyperuricaemia and gout in Taiwan aborigines. Br J Rheumatol. 1998;37:258-62.
13. Lin KC, Lin HY, Chou P. Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen. J Rheumatol. 2000;27:1045-50.
14. Chang HY, Pan WH, Yeh WT, Tsai KS. Hyperuricemia and gout in Taiwan: results from the Nutritional and Health Survey in Taiwan (1993-96). J Rheumatol. 2001;28:1640-6.
15. Lai SW, Liu CS, Lin T, Lin CC, Lai HC, Liao KF. Prevalence of gout and hyperuricemia in Taiwan: a hospital-based, cross-sectional study. South Med J. 2009;102:772-3.
16. Kuo CF, Yu KH, Luo SF, Chiu CT, Ko YS, Hwang JS, et al. Gout and risk of non-alcoholic fatty liver disease. Scand J Rheumatol. 2010;39:466-71.
17. Chuang SY, Lee SC, Hsieh YT, Pan WH. Trends in hyperuricemia and gout prevalence: Nutrition and Health Survey in Taiwan from 1993-1996 to 2005-2008. Asia Pac J Clin Nutr. 2011;20:301-8.
18. Kuo CF, Grainge MJ, See LC, Yu KH, Luo SF, Valdes AM, et al. Familial aggregation of gout and relative genetic and environmental contributions: a nationwide population study in Taiwan. Ann Rheum Dis. 2015;74:369-74. doi:10.1136/annrheumdis-2013-204067.
19. Friedlaender JS, Friedlaender FR, Reed FA, Kidd KK, Kidd JR, Chambers GK, et al. The genetic structure of Pacific Islanders. PLoS Genet. 2008;4:e19.
20. Klemp P, Stansfield SA, Castle B, Robertson MC. Gout is on the increase in New Zealand. Ann Rheum Dis. 1997;56:22-6.
21. Yu TF, Gutman AB. Efficacy of colchicine prophylaxis in gout: prevention of recurrent gouty arthritis over a mean period of five years in 208 gouty subjects. Ann Intern Med. 1961;55:179-92.
22. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19:335-51.
23. McAdams MA, Maynard JW, Baer AN, Kottgen A, Clipp S, Coresh J, et al. Reliability and sensitivity of the self-report of physician-diagnosed gout in the campaign against cancer and heart disease and the atherosclerosis risk in the community cohorts. J Rheumatol. 2011;38:135-41.
24. Picavet HS, Hazes JM. Prevalence of self reported musculoskeletal diseases is high. Ann Rheum Dis. 2003;62:644-50.
25. O'Sullivan JB. Gout in a New England town: a prevalence study in Sudbury, Massachusetts. Ann Rheum Dis. 1972;31:166-9.
26. Arromdee E, Michet CJ, Crowson CS, O'Fallon WM, Gabriel SE. Epidemiology of gout: is the incidence rising? J Rheumatol. 2002;29:2403-6.
27. Usbott RD, Brand FN, Kannel WB, Castelli WP. Gout and coronary heart disease: the Framingham Study. J Clin Epidemiol. 1988;41:237-42.
28. Hochberg MC, Thomas J, Thomas DJ, Mead L, Levine DM, Klag MJ. Racial differences in the incidence of gout. The role of hypertension. Arthritis Rheum. 1995;38:628-32.
29. Stewart OJ, Silman AJ. Review of UK data on the rheumatic diseases-4. Gout. Br J Rheumatol. 1990;29:485-8.
30. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher Jr HR, Saag KG. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis. 2005;64:267-72.
31. Maynard JW, McAdams-Demarco MA, Law A, Kao L, Gelber AC, Coresh J, et al. Racial differences in gout incidence in a population-based cohort: atherosclerosis risk in communities study. Am J Epidemiol. 2014;179:576-83.
32. Yu KH, Luo SF. Younger age of onset of gout in Taiwan. Rheumatology (Oxford). 2003;42:166-70.
33. Hall AP, Barry PE, Dawber TR, McNamara PM. Epidemiology of gout and hyperuricemia: a long-term population study. Am J Med. 1967;42:27-37.
34. Nishioka N, Mikanagi K. Clinical features of 4,000 gouty subjects in Japan. Adv Exp Med Biol. 1980;122A:47-54.
35. Li R, Sun J, Ren LM, Wang HY, Liu WH, Zhang XW, et al. Epidemiology of eight common rheumatic diseases in China: a large-scale cross-sectional survey in Beijing. Rheumatology (Oxford). 2012;51:721-9.
36. Hosoya T, Ohno I, Ichida K, Peters GJ. Gout and hyperuricemia in Japan: perspectives for international research on purines and pyrimidines in man. Nucleosides Nucleotides Nucleic Acids. 2011;30:1001-10.
37. Ko YC, Wang TN, Tsai LY, Chang FT, Chang SJ. High prevalence of hyperuricemia in adolescent Taiwan aborigines. J Rheumatol. 2002;29:837-42.
38. Freeman J, Hutchison GB. Prevalence, incidence and duration. Am J Epidemiol. 1980;112:707-23.
39. Alho JM. On prevalence, incidence, and duration in general stable populations. Biometrics. 1992;48:587-92.
40. Tsay GJ, Yu KH, Liang TH, Tsai W-C, Wei CC, Hsieh TY. Taiwan guideline for the management of gout and hyperuricaemia. Taipei: Taiwan Rheumatology Association. 2007. http://imohw.tmu.edu.tw/idohtmu/wp-content/uploads/2013/04/04%E5%8F%B0%E7%81%A3%E7%97%9B%E9%A2%A8%E8%88%87%E9%AB%98%E5%B0%BF%E9%85%B8%E8%A1%80%E7%97%87%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95.pdf. Accessed 10 Feb 2015.
41. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Saag KG. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology (Oxford). 2005;44:1038-42.
42. Roddy E, Mallen CD, Hider SL, Jordan KP. Prescription and comorbidity screening following consultation for acute gout in primary care. Rheumatology (Oxford). 2010;49:105-11.
43. Neogi T, Hunter DJ, Chaisson CE, Allensworth-Davies D, Zhang Y. Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study. J Rheumatol. 2006;33:104-9.
44. Barber C, Thompson K, Hanly JG. Impact of a rheumatology consultation service on the diagnostic accuracy and management of gout in hospitalized patients. J Rheumatol. 2009;36:1699-704.
45. Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006;81:925-34.
46. Reaves E, Arroll B. Management of gout in a South Auckland general practice. J Prim Health Care. 2014;6:73-8.
47. Dalbeth N, House ME, Horne A, Petrie KJ, McQueen FM, Taylor WJ. Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout. BMC Musculoskelet Disord. 2012;13:174.
48. Roddy E, Zhang W, Doherty M. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann Rheum Dis. 2007;66:1311-5.
49. Spencer K, Carr A, Doherty M. Patient and provider barriers to effective management of gout in general practice: a qualitative study. Ann Rheum Dis. 2012;71:1490-5.
50. Reach G. Treatment adherence in patients with gout. Joint Bone Spine. 2011;78:456-9.
51. Solomon DH, Avorn J, Levin R, Brookhart MA. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis. 2008;67:609-13.
52. Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis. 2013;72:826-30.
53. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20:895-900.
54. Kellgren JH, Jeffrey MR, Ball J, editors. The epidemiology of chronic rheumatism. Oxford: Blackwell. 1963.